Are results from immunotherapy in lung cancer durable?


Are responses to immunotherapy for lung cancer durable?

According to data presented at AACR’s 2017 Annual Meeting, from a number of clinical trials, the answer appears to be “Yes.” For many patients whose cancers responded to treatment with an immune checkpoint inhibitor, particularly those that target the immune checkpoint proteins PD1 and PDL1, the responses appeared to have lasted for several years.

Read the article: